Influx Healthtech Limited IPO...
19 Jun, 2025
Influx Healthtech Limited IPO
Influx Healthtech Limited, a CDMO based in Mumbai is launching its Initial Public Offering (IPO) to raise around ₹55.63 crore. The IPO includes a fresh issue of 46.94 lakh shares worth about ₹45.07 crore and an offer-for-sale (OFS) of 11 lakh shares valued at roughly ₹10.56 crore. Shares are priced between ₹91 and ₹96 each. Subscriptions will be taken from June 18 to June 20, 2025; the smallest lot is 1,200 shares. Traders can expect the stock to debut on the NSE SME platform on June 25, 2025.
Company Background
Influx Healthtech Limited has been operating as a CDMO in the health and wellness sector since its incorporation in September 2020. The company specializes in contract manufacturing, providing product development and manufacturing services for nutraceuticals, cosmetics, ayurvedic products and veterinary feed supplements. Its client base includes notable brands such as Bling Brands, Pursuit of Wellness, Aarkios Health, HSHS Nutraceuticals Limited, Novus Life Science, Bruder Life Science, Fredun Pharmaceuticals and BigFlex Lifescience.
Operations & Product Range
Facility & Production:
Influx Healthtech operates three manufacturing facilities in Thane, Maharashtra, within an area of 9,676 sq. ft., 13,000 sq. ft. and 14,000 sq. ft respectively. These facilities are equipped to manufacture a wide variety of products, including tablets, capsules, softgels, jellies, oral dissolving films (ODFs), effervescent tablets, cosmetics, herbal formulations, veterinary and homecare products.
Brands & Market Presence:
The company supports nutraceutical and cosmetic firms by providing end-to-end services, from product development to regulatory support. Its strong CDMO capabilities have established Influx Healthtech as a trusted partner for several leading brands in the wellness and pharma sectors.
Revenue Channels
Influx Healthtech generates revenue primarily through:
- Contract manufacturing for third-party brands in nutraceuticals, cosmetics, ayurvedic and veterinary segments.
- Product development and regulatory support services for client brands.
- The company reported a revenue of ₹104.99 crore and a net profit of ₹13.37 crore for FY25, showing consistent growth in both revenue and profitability.
Management & Shareholding
Promoters & Shareholding:
Mr. Munir Abdul Ganee Chandniwala, Mrs. Shirin Munir Ahmed Chandniwala and Mr. Abdul Ganee Abdul Rasul Chandniwala are included in the promoters of the company. Promoters hold 99.85% shares before the IPO but after the IPO, it will decrease to 73.53%.
Details of the promoters and their shareholding percentages are not explicitly listed in the available sources. However, the company is led by experienced professionals in the healthcare manufacturing sector and the IPO includes both a fresh issue and an offer-for-sale by existing shareholders.
Board Members:
The company is led by experienced professionals in the healthcare manufacturing sector on its board. The company employs around 163–165 permanent staff as of June 2025, which shows a stable operational structure.
WHAT IS GMP?
GMP (Grey Market Premium) is the difference between the IPO price and the grey market price. It is the premium amount paid for the traded IPO shares. It plays an important role in IPOs as it reflects how the IPO would react on the listing day.
A grey market is a place where shares/stocks are traded before being listed officially on the stock exchange.
Influx Healthtech Limited IPO
| GMP Date | IPO Price | GMP | Last Updated |
|---|---|---|---|
| - | - | - | - |
**The GMP prices displayed here are solely for informational purposes related to the grey market news. India IPO does not engage in or facilitate grey market trading, nor are these rates (sub2) indicative of any trading activity. We also do not recommend or endorse participation in the grey market.**
Influx Healthtech Limited IPO Details
| Detail | Description |
|---|---|
| IPO Date | June 18, 2025 to June 20, 2025 |
| Listing Date | - |
| Face Value | ₹10 per share |
| Issue Price Band | ₹91 to ₹96 per share |
| Lot Size | 1,200 Shares |
| Total Issue Size (Ex Market Maker) | 57,94,800 shares (aggregating up to ₹55.63 Cr) |
| Fresh Issue (Ex Market Maker) | 46,94,400 shares (aggregating up to ₹45.07 Cr) |
| Offer for Sale (Ex Market Maker) | 11,00,400 shares of ₹10 (aggregating up to ₹10.56 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 1,81,50,000 shares |
| Share Holding Post Issue | 2,31,50,400 shares |
| Market Maker Portion | 3,06,000 shares |
Influx Healthtech Limited IPO Timeline
| Detail | Description |
|---|---|
| IPO Open Date | Wed, Jun 18, 2025 |
| IPO Close Date | Fri, Jun 20, 2025 |
| Tentative Allotment | Mon, Jun 23, 2025 |
| Initiation of Refunds | Tue, Jun 24, 2025 |
| Credit of Shares to Demat | Tue, Jun 24, 2025 |
| Tentative Listing Date | Wed, Jun 25, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on June 20, 2025 |
Influx Healthtech Limited IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 1200 | ₹1,15,200 |
| Retail (Max) | 1 | 1200 | ₹1,15,200 |
| HNI (Min) | 2 | 2,400 | ₹2,30,400 |
Influx Healthtech Limited IPO Promoter Holding
| Share Holding Pre Issue | Share Holding Post Issue |
|---|---|
| - | - |
Competitive Strength:
- ● Diverse Product Portfolio
- ● Strong Clientele
- ● Well-Equipped Manufacturing Plants
- ● Financial Growth
- ● Regulatory Compliance
Influx Healthtech Limited IPO Financial Information
| Period Ended | Assets | Revenue | Profit After Tax | Net Worth | Total Borrowing | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31 Mar 2025 | 70.3 | 104.99 | 13.37 | 36.15 | 0.22 | |||||||||||||||||||||||||||||||||||
| 31 Mar 2024 | 41.1 | 100.1 | 11 | 22.87 | 0.32 | |||||||||||||||||||||||||||||||||||
| 31 Mar 2023 | 28.3 | 76.07 | 7.2 | 11.65 | 0.8 | |||||||||||||||||||||||||||||||||||
| Amount in ₹ Crore | ||||||||||||||||||||||||||||||||||||||||
Key Performance Indicator
| KPI | Values |
|---|---|
| ROE | 36.98% |
| ROCE | 49.17% |
| Debt/Equity | 0.01 |
| RoNW | 36.98% |
| PAT Margin | 12.75 |
| Price to Book Value | 7.62 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 7.36 | 5.77 |
| P/E (x) | 13.04 | 16.63 |
IPO Objectives
The primary objectives of the IPO are:
- Setting up two new manufacturing units in the nutraceutical and veterinary segments (₹34.19 crore).
- Purchase of new machinery to enhance production capacity.
- General corporate purposes to support future growth and operational efficiency.
Conclusion
Overall, Influx Healthtech Limited’s IPO offers investors an opportunity to participate in the growth of a rapidly expanding CDMO in the health and wellness sector. With a strong product portfolio, established client relationships and ambitious expansion plans, the company is well-positioned for future growth. However, as with all SME IPOs, investors should carefully review the company’s fundamentals, market conditions and risk factors before investing.
RHP:
DRHP:
Read more :
Frequently asked Questions (FAQs )
-
1. What is the size of the Influx Healthtech first public offering?
Through a combination of a fresh issuance and an offer-for-sale, the IPO seeks to raise around 55.63 to 58.57 crore.
-
2. When does the initial public offering (IPO) open and close?
On June 18, 2025, the IPO will open and on June 20, 2025, it will close.
-
3. For retail investors, what is the minimum lot size?
Retail investors must apply for a minimum of 1,200 shares per lot, requiring an investment of ₹1,09,200–₹1,15,200 depending on the cutoff price.
-
4. When will the shares be listed?
On June 25, 2025, the shares are anticipated to go live on the NSE SME platform.
-
5. How will the money from the IPO be spent?
The money will be utilised for general business operations, machinery purchases and the establishment of new production facilities.
-
6. What are the primary goods and services offered by the business?
Influx Healthtech manufactures nutraceuticals, cosmetics, ayurvedic products and veterinary feed supplements and offers product development and regulatory support.
-
7. Who are the lead manager, registrar and market maker for the IPO?
Rarever Financial Advisors Pvt. Ltd. is the book-running lead manager, Maashitla Securities Pvt. Ltd. is the registrar and RK Stock Holding Pvt. Ltd. is the market maker.
-
8. What are the company’s recent financials?
The company reported ₹104.99 crore in sales and ₹13.37 crore in net profit for FY25.
